Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.230
-0.130 (-5.51%)
At close: Aug 1, 2025, 4:00 PM
2.210
-0.020 (-0.90%)
After-hours: Aug 1, 2025, 7:52 PM EDT

Company Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.

Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.

The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4.

The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc.
Nuvation Bio logo
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees220
CEODavid Hung

Contact Details

Address:
1500 Broadway, Suite 1401
New York, New York 10036
United States
Phone332 208 6102
Websitenuvationbio.com

Stock Details

Ticker SymbolNUVB
ExchangeNYSE
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001811063
CUSIP Number67080N101
ISIN NumberUS67080N1019
Employer ID85-0862255
SIC Code2834

Key Executives

NamePosition
Dr. David T. Hung M.D.Founder, President, Chief Executive Officer and Chairman
Dr. Gary Hattersley Ph.D.Chief Scientific Officer
Colleen SjogrenChief Commercial Officer
Philippe Pierre SauvageChief Financial Officer and Principal Financial Officer
Moses Makunje CPAVice President of Finance and Principal Accounting and Financial Officer
Dr. Stephen Dang Ph.D.Senior Vice President, General Counsel and Corporate Secretary
Stacy MarkelChief People Officer
Dr. David C. Hanley Ph.D.Chief Technical Operations Officer
Kerry A. WentworthChief Regulatory Officer
Dr. David Liu M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jun 11, 20258-KCurrent Report
May 23, 20258-KCurrent Report
May 12, 2025SCHEDULE 13G/AFiling
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
May 2, 2025144Filing
Apr 28, 2025SCHEDULE 13G/AFiling
Apr 8, 2025ARSFiling
Apr 8, 2025DEF 14AOther definitive proxy statements